Emactuzumab

Drug Profile

Emactuzumab

Alternative Names: Anti-colony stimulating factor-1 receptor monoclonal antibody - Roche; Anti-CSF-1R monoclonal antibody - Roche; Anti-macrophage colony stimulating factor receptor monoclonal antibody - Roche; CSF-1R MAb solid tumours - Roche; RG-7155; RO-5509554

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis; Giant cell tumour of tendon sheath
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Giant cell tumour of tendon sheath; Pigmented villonodular synovitis

Most Recent Events

  • 30 Sep 2016 Genentech and M.D. Anderson Cancer Center plan the phase II REDIRECT trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT02923739)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in France (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top